Telomir Pharmaceuticals (TELO) Cash from Operations (2023 - 2025)
Telomir Pharmaceuticals (TELO) posted Cash from Operations of 1200000.0 for Q4 2025, down 33.33% sequentially from 900000.0 in Q3 2025, and down 98.08% YoY from 62583471.07 in Q4 2024.
Telomir Pharmaceuticals (TELO) Cash from Operations (2023 - 2025) Analysis & Trends
Telomir Pharmaceuticals has reported Cash from Operations for 3 years, with the latest figure at 1200000.0 in Q4 2025.
- Quarterly Cash from Operations fell 98.08% year-over-year to 1200000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 3700000.0 (up 27.03% YoY) and the FY2025 annual result came in at 3700000.0, up 27.03% from the prior year.
- Cash from Operations slipped to 1200000.0 in Q4 2025 per TELO's latest filing, from 900000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 33577.0 in Q2 2023 and troughed at 2003265.0 in Q3 2023.
- A 3-year average of 1052518.67 and a median of 951181.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2024 and 2025: Cash from Operations tumbled 4435.38% in 2024, then soared 54.03% in 2025.
- Over 3 years, Cash from Operations stood at 1087215.0 in 2023, then surged by 44.28% to 605808.0 in 2024, then tumbled by 98.08% to 1200000.0 in 2025.
- According to Business Quant data, Cash from Operations over the past three periods registered 1200000.0, 900000.0, and 700000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.52 Bn | 132.67 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.55 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 65.31 Bn | 60.13 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.77 Bn | 56.64 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 42.26 Bn | 37.16 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.19 Bn | 27.88 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.71 Bn | 10.31 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | 728.46 Mn |
| 10 | Telomir Pharmaceuticals | 69.96 Mn | 69.96 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.20 Mn |
| Dec 31, 2025 | -1.20 Mn |
| Sep 30, 2025 | -900,000.00 |
| Sep 30, 2025 | -900,000.00 |
| Jun 30, 2025 | -700,000.00 |
| Jun 30, 2025 | -700,000.00 |
| Mar 31, 2025 | -900,000.00 |
| Mar 31, 2025 | -900,000.00 |
| Dec 31, 2024 | -605,808.00 |
| Dec 31, 2024 | -605,808.00 |
| Sep 30, 2024 | -1.00 Mn |
| Sep 30, 2024 | -1.00 Mn |
| Jun 30, 2024 | -1.52 Mn |
| Jun 30, 2024 | -1.52 Mn |
| Mar 31, 2024 | -1.94 Mn |
| Mar 31, 2024 | -1.94 Mn |
| Dec 31, 2023 | -1.09 Mn |
| Dec 31, 2023 | -1.09 Mn |
| Sep 30, 2023 | -2.00 Mn |
| Sep 30, 2023 | -2.00 Mn |